[Comparative evaluation of proliferative activity of breast tumors of different estrogen-progesterone receptor status].
Immunological investigation involving 100 estrogen-progesterone receptor negative (RE-RP-) and 71 estrogen-progesterone receptor positive (RE+RP+) breast cancer patients demonstrated that Ki-67 expression in the former group was twice (49.8%) that in the latter (25.9%). Low Ki-67 expression was found in 39% of RE-RP-tumors whereas high expression--in 28% of RE+RP+ tumors.